** Brokerage Truist downgrades drugmaker Biogen BIIB.O to "hold" from "buy", trims PT to $142 from $199
** New PT implies a 13.6% upside to the stock's last close
** Truist says the downgrade is due to weak growth prospects in Biogen'ss existing products and no low-risk new drug in development
** Brokerage is no longer optimistic about Biogen's Alzheimer's drug opportunity, and expects only modest growth for Leqembi
** Expects limited growth for Zurzuvae and believes Skyclarys sales have peaked and says Biogen's late-stage pipeline is seen as high-risk
** As of last close, BIIB stock down 18.3% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.